Abstract
Pharmacological treatment of hypercalcemia is essential for patients with parathyroid carcinoma and intractable primary hyperparathyroidism (PHPT). Use of the calcimimetic cinacalcet hydrochloride (cinacalcet) is an option to treat such patients. We investigated the efficacy and safety of cinacalcet in Japanese patients with parathyroid carcinoma and intractable PHPT. Five Japanese patients with parathyroid carcinoma and two with intractable PHPT were enrolled in an open-label, single-arm study consisting of titration and maintenance phases. Cinacalcet doses were titrated until the albumin-corrected serum calcium concentration decreased to 10.0 mg/dL or less or until dose escalation was considered not necessary or feasible. Serum calcium concentration at the baseline was 12.1 ± 1.3 mg/dL (mean ± standard deviation; range 10.4–14.6 mg/dL) and decreased to 10.1 ± 1.6 mg/dL (range 8.6–13.3 mg/dL) at the end of the titration phase with cinacalcet at a dosage of up to 75 mg three times a day. At the end of the titration phase, at least a 1 mg/dL reduction in serum calcium concentration from the baseline was observed in five patients (three with carcinoma and two with PHPT), and it decreased to the normocalcemic range in five patients (three with carcinoma and two with PHPT). Common adverse events were nausea and vomiting. One patient discontinued participation in the study because of an adverse event, liver disorder. Cinacalcet effectively relieved hypercalcemia in 60% of the Japanese patients with parathyroid carcinoma and might be effective in those with intractable PHPT. The drug might be tolerable and safe at a dosage of at most 75 mg three times a day.
Similar content being viewed by others
References
Cordeiro AC, Montenegro FL, Kulcsar MA, Dellanegra LA, Tavares MR, Michaluart P Jr, Ferraz AR (1998) Parathyroid carcinoma. Am J Surg 175:52–55
Fraker DL (2000) Update on the management of parathyroid tumors. Curr Opin Oncol 12:41–48
Shane E (2001) Parathyroid carcinoma. J Clin Endocrinol Metab 86:485–493
Stock JL, Marcus R (2001) Medical management of primary hyperparathyroidism in the United States. In: Bilezikian JP (ed) The parathyroids. Academic, San Diego, pp 459–474
Nemeth EF, Steffey ME, Hammerland LG, Hung BCP, Van Wagenen BC, Delmar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95:4040–4045
Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM et al (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803–3808
Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA et al (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135–141
Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083–1088
Au WY (1975) Calcitonin treatment of hypercalcemia due to parathyroid carcinoma: synergistic effect of prednisone on long-term treatment of hypercalcemia. Arch Intern Med 135:1594–1597
Newrick PG, Braatvedt GD, Webb AJ, Sheffield E, Corrall RJM (1994) Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. Postgrad Med J 70:231–232
Mann K (1985) Oral biphosphonate therapy in metastatic parathyroid carcinoma. Lancet 1:101–102
Jungst D (1984) Disodium clodronate effective in management of severe hypercalcaemia caused by parathyroid carcinoma. Lancet 2:1043
Levi R, Ben-Dov IZ, Lavi-Moshayoff V, Dinur M, Martin D, Naveh-Many T, Silver J (2006) Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol 7:107–112
Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627–635
Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M (2009) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 94:2766–2772
Acknowledgements
The authors thank all the investigators, staff, and patients who participated in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
This study was sponsored by Kyowa Hakko Kirin Co., Ltd.
About this article
Cite this article
Takeuchi, Y., Takahashi, S., Miura, D. et al. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J Bone Miner Metab 35, 616–622 (2017). https://doi.org/10.1007/s00774-016-0797-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-016-0797-0